ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer.
ARIMIDEX is approved for the initial treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and for the treatment of postmenopausal women with advanced breast cancer that has progressed following treatment with tamoxifen. Patients with hormone receptor-negative disease and patients who did not previously respond to tamoxifen therapy rarely responded to ARIMIDEX.
For more information, see your doctor.
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US consumers only.
ARIMIDEX is a registered trademark and AZ&Me is a trademark of the AstraZeneca group of companies.
All rights reserved. 1244803-2628202 Last Updated 5/13
Like this badge and show your support for the ARIMIDEX DIRECT Program. Copy and paste the code below to publish the badge to your Web site or blog.
ARIMIDEX is approved for adjuvant treatment (treatment following surgery with or without radiation) of postmenopausal women with hormone receptor-positive early breast cancer. Click here for additional information
Important Safety Information About ARIMIDEXPrescription ARIMIDEX is only for postmenopausal women. ARIMIDEX should not be taken if you are pregnant because it may harm your unborn child. Do not take ARIMIDEX if you are allergic to any of its ingredients. Click here for additional safety information
If you have been diagnosed with HR+ metastatic breast cancer, there are options. Learn more about your options